Loading...
•
Sep 30, 2021
Cytokinetics Q3 2021 Earnings Report
Reported financial results for the third quarter of 2021.
Key Takeaways
Cytokinetics reported a net loss of $76.1 million, or $0.95 per share, for the third quarter of 2021. Revenues for the quarter were $5.4 million. Cash, cash equivalents and investments totaled $668.9 million at September 30, 2021.
Shared positive results from REDWOOD-HCM.
Conducted start-up activities for SEQUOIA-HCM, Phase 3 trial of aficamten.
Started COURAGE-ALS, Phase 3 trial of reldesemtiv.
Advancing towards submitting the NDA for omecamtiv mecarbil.
Forward Guidance
Cytokinetics is on track to submit the NDA for Omecamtiv Mecarbil in Q4 2021 and expects results from Cohort 3 of REDWOOD-HCM in Q1 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...